Chiesi Global Rare Diseases...announced today that the U.S. Food and Drug Administration (FDA) has approved JUXTAPID (lomitapide) capsules for pediatric use in homozygous familial hypercholesterolemia (HoFH) for children 2 years of age and older (GlobeNewswire) - Mar 3, 2026 - "The FDA's approval is grounded on evidence from a Phase 3, open-label, multicenter study (APH-19) evaluating the safety and efficacy of JUXTAPID in 43 pediatric participants aged 5 to 17 years with HoFH who were receiving standard-of-care lipid-lowering therapy and a low-fat diet."
FDA approval • Homozygous Familial Hypercholesterolemia
|